Side effects and precautions of Ripotinib

Repotrectinib is a targeted therapy for ROS1-positive non-small cell lung cancer. While it shows significant efficacy, it also has specific risks of adverse reactions. Understanding the side effects, clinical use precautions and treatment effect characteristics of this drug is of great significance to both doctors and patients in formulating reasonable treatment strategies.

Side effects of Ripotinib

may cause multi-system adverse reactions during clinical application. The following are side effects with a high incidence rate that require special attention.

Nervous system toxicity

Most patients may experience central nervous system adverse reactions, mainly manifested as dizziness, ataxia and cognitive impairment. These symptoms usually appear in the early stages of medication, and a small number of patients may develop to grade 3-4 severity, affecting their daily life.

Respiratory complications

A small number of patients develop interstitial lung disease/pneumonitis, with clinical manifestations of progressive dyspnea, dry cough and hypoxemia.

Metabolic abnormalities

Patients may develop hyperuricemia, myalgia, and elevated creatine kinase. These abnormalities usually appear within the first month of treatment.

After understanding the characteristics of these side effects, it is crucial to take standardized prevention and monitoring measures to ensure the safety of treatment.

Precautions for Ripotinib

Special attention should be paid to the following key matters when using Ripotinib.

Pre-treatment assessment

Before medication, the positive status of ROS1 must be confirmed, and baseline liver function, CPK and uric acid tests must be completed. Women of childbearing age need to take a pregnancy test and be instructed to use non-hormonal contraceptive methods (because drugs may reduce the effectiveness of hormonal contraception).

Monitoring during treatment

Liver function, CPK and uric acid will be monitored every 2 weeks in the first month of treatment, and then reviewed monthly. The development of myalgia, dyspnea, or neurological symptoms requires immediate evaluation. It is recommended to keep a symptom diary to record the frequency and duration of dizziness attacks.

Principles of dose adjustment

If grade 3 adverse reactions occur, the medication needs to be suspended. After recovery, the dose is reduced to 120 mg bid to continue treatment. The drug should be permanently discontinued if interstitial lung disease or grade 4 hepatotoxicity occurs. Fracture patients need to evaluate the risk-benefit ratio before deciding whether to continue treatment.

While standardizing the management of side effects, understanding the therapeutic effects of drugs can help formulate individualized treatment plans.

Efficacy of Ripotinib

Ripotinib has shown significant clinical value in the treatment of ROS1-positive non-small cell lung cancer.

Objective response rate

Key clinical trials show that initially treated patients have a higher objective response rate, a longer median progression-free survival, and a longer median duration of response.

Advantage of target coverage

As a multi-target inhibitor, reprotinib is effective against ROS1, ALK and NTRK fusion genes. Its unique molecular structure can overcome common drug-resistant mutations, such as ROS1 G2032R, etc.

Convenience of medication

Oral administration improves patient compliance. The standard dose of 160 mg qd is started and adjusted to bid after 14 days, which is helpful to gradually adapt to the drug response. The blood drug concentration is stable and individual differences are small.

Reputinib provides a new treatment option for patients with refractory ROS1-positive lung cancer. Patients should take medication regularly under the guidance of professional physicians and maintain regular follow-up.